BSH 2022 | First- and second-line treatment in DLBCL

Sridhar Chaganti, MD, PhD, MRCP, FRCPath, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, gives a detailed overview of first- and second-line treatment in diffuse large B-cell lymphoma (DLBCL). Dr Chaganti first discusses frontline treatment, drawing focus on the use of R-CHOP, and briefly discusses the POLARIX study (NCT03274492) evaluating polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy in patients with DLBCL. Following this, Dr Chaganti discusses second-line treatment options for transplant-eligible patients and clinical trials in this area, including the ZUMA-7 (NCT03391466), TRANSFORM (NCT03575351), and BELINDA (NCT03570892) trials. To conclude, Dr Chaganti discusses the unmet need in therapeutic options for transplant-ineligible patients, and the promise of novel agents including polatuzumab, bendamustine and rituximab (pola-BR) and tafasitamab. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.